Phase I dose-escalation drug-interaction study of sorafenib and bevacizumab in combination with paclitaxel in patients with solid tumors.

Trial Profile

Phase I dose-escalation drug-interaction study of sorafenib and bevacizumab in combination with paclitaxel in patients with solid tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 May 2016

At a glance

  • Drugs Sorafenib (Primary) ; Bevacizumab; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
    • 10 Sep 2014 Planned End Date changed from 1 Jan 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 16 Aug 2012 Additional lead trial investigator (Daniela E Matei) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top